Advances in cancer immunotherapy: Strategies and innovations strategies for adoptive immunotherapy of cancer
نویسندگان
1 Thalassemia and Hemoglobinopathy Research Center, Health Research Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
2 Thalassemia and Hemoglobinopathy Research Center, Health Research Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
3 Clinical Research Development Unit, Golestan Hospital, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
4 Aryogen Pharmed Biopharmaceutical Research Center, Alborz University of Medical Science, Karaj, Iran
5 Student Research Committee, School of Allied Medical Sciences, Shahroud University of Medical Sciences, Shahroud, Iran
doi
10.22038/ijbms.2025.88384.19090چکیده
Cancer immunotherapy has emerged as a transformative approach in oncology, offering alternatives beyond traditional treatments. This narrative review focuses on major innovations, including adoptive cell therapy (ACT), chimeric antigen receptor T-cells (CAR-T), T-cell receptor (TCR) engineering, monoclonal antibodies (mAbs), bispecific antibodies (BsAbs), and immune checkpoint inhibitors (ICIs). The central aim of this article is to analyze how these technologies improve antitumor responses and help overcome resistance in hematologic and solid tumors. This narrative review combines the latest findings from clinical and preclinical studies to highlight therapeutic potentials and challenges. Key observations include the clinical success of CAR-T cells in treating blood cancers, the expanding application of ICIs in solid tumors, and the evolving structure-function relationship of BsAbs in recruiting immune effectors. This paper concludes by evaluating the current limitations of these immunotherapeutic strategies and discusses future directions for integrating them into personalized cancer therapy.
